Skip to search formSkip to main contentSkip to account menu

MK 826

Known as: MK-826 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Carbapenems

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
Ertapenem. A review of its microbiologic, pharmacokinetic and clinical aspects.
Ertapenem sodium (trade name Invanz, also designated as MK-0826, MK-826 and L-749345), manufactured by Merck & Co., Inc. is a… 
2001
2001
Chapter 9. Recent developments in antibacterial research
2000
2000
In Vitro Activities of MK-826 (L-749,345) against 363 Strains of Anaerobic Bacteria
ABSTRACT The activity of MK-826 was compared to the activities of cefoxitin, ceftriaxone, imipenem, and meropenem against 363… 
1999
1999
Dose-dependent plasma clearance of MK-826, a carbapenem antibiotic, arising from concentration-dependent plasma protein binding in rats and monkeys.
After intravenous administration of MK-826, a new carbapenem antibiotic, the compound exhibited nonlinear pharmacokinetics in… 
Highly Cited
1998
Highly Cited
1998
In Vivo Activity and Pharmacokinetic Evaluation of a Novel Long-Acting Carbapenem Antibiotic, MK-826 (L-749,345)
ABSTRACT MK-826 (formerly L-749,345), is a potent 1-β-methyl carbapenem with a long half-life and broad spectrum of activity… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)